Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

The following is a summary of “Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis ...

Both of these U.S. dividend kings have increased payouts for over 50 consecutive years. The post RRSP Investors: Buy These ...

In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...

US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...

The following is a summary of “Opioid Use and Healthcare Utilization in Adults With Psoriatic Arthritis and Ankylosing ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

By following these strategies, you can better manage morning stiffness and improve your comfort and mobility as you start ...

Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...